BIOCARDIA - Key Persons

Job Titles:

• Chairman of the Board of Directors

Andrew Scott Blank is Chairman of our board of directors and was appointed to our board of directors in October 2019. Mr. Blank is President of National Brands, Inc., an investment group that was one of the largest Anheuser-Busch beer distributors prior to divestiture of those operations, and has served in that capacity since March 1993. Mr. Blank also currently serves as President of WareITis Technologies, developer of one of the foremost enterprise level content management software suites called Records Studio, President of Archive America, one of the country's largest family-owned document storage firms, President of Seaboard Warehouse Terminals, Seaboard Chicago U.S. and Seaboard Warehouse, a group of companies providing nationwide third-party logistics services, and President of the Blank Family Foundation, a private family foundation that provides philanthropic support to worthy charitable organizations. Mr. Blank also currently serves on the board of directors of Neumentum, Inc. Mr. Blank holds a bachelor's degree in business from the University of Miami.

Job Titles:

• Member of the Board of Directors
• President and Chief Executive Officer of Earlens Corporation

Bill Facteau was appointed to our board of directors effective October 18, 2023. Mr. Facteau is the President and Chief Executive Officer of Earlens Corporation, which is focused on transforming the hearing aid industry with its novel and proprietary light-based technology, and has served in that capacity since November 2013. Prior to joining Earlens, Mr. Facteau served as President and Chief Executive Officer of Acclarent, the company that created Balloon Sinuplasty. Mr. Facteau previously served as a director on the board of a number of companies, including Acclarent, Aerin Medical, PROCEPT BioRobotics, Neotract, CVI, Cabachon and ExploraMed. Mr. Facteau holds a bachelor's degree from the University of Connecticut.

Job Titles:

• Member of the Management Team
• Vice President of Clinical
• VP of Clinical View Profile

Ms. Holmes-Higgin has served as Vice President of Clinical since December 2019 and has been with the Company since August 2017, also serving as Senior Director, Clinical Operations. Ms. Holmes-Higgin has clinical research experience supporting pre-and post-market medical device and implant technologies utilized in several different types of interventional, minimally-invasive, and surgical specialties. Before joining our Company, Ms. Holmes-Higgin served as Senior Director, Clinical Affairs at Benvenue Medical, where she led post-market clinical efforts to enhance the scientific publications portfolio for their spinal applications products, Senior Director, Clinical Research at Pulmonx, where she supported OUS clinical research activities and publications and led critical efforts to develop and start-up their key U.S. IDE clinical trial for an implant intended for treatment of emphysema. Prior to that, Ms. Holmes-Higgin was Senior Director, Clinical Affairs at ArthroCare, where she led the clinical research group supporting pre- and post-market research activities, for both company-sponsored and investigator-initiated projects for all four of the Company's business units. Ms. Holmes-Higgin has authored numerous clinical research medical journal publications in a number of health/medical specialties. She earned a Bachelor of Science degree in Secondary Education from University of Portland, a Master of Science degree in Exercise Science & Health Promotion from Arizona State University, and a Master of Public Health degree, specializing in Epidemiology & Biostatistics, from Oregon Health Sciences University.

Job Titles:

• Member of the Management Team
• VP of Devices View Profile

Ed Gillis joined BioCardia in 2020. Prior to joining us, Ed served as Chief Technical Officer and as President and Chief Executive Officer of ReVENT Medical, Inc., a company he founded. Prior to that he served as Vice President of Research and Development for SineXus (now Intersect ENT) and Apneon, an obstructive sleep apnea company. Ed was VP of Manufacturing and Engineering for Durect Corporation a pharmaceutical company developing drug delivery systems, catheters, and other delivery platforms. Previously, Ed worked in senior positions in manufacturing and product development for EndoTex Interventional Systems and Cardiac Pathways Corporation (both acquired by Boston Scientific) and engineering positions at Spectranetics Corporation, Guidant Corporation and Baxter Healthcare. He has built from scratch and provided leadership for early stage companies as well as R&D and manufacturing organizations. Ed received his Bachelor of Science in Biology and Master of Science in Plastics Engineering from The University of Massachusetts Lowell. He holds 34 US patents with 100+ issued and pending worldwide and is named author on scientific publications in the areas of obstructive sleep apnea, catheter design and drug delivery.

Job Titles:

• Member of the Board of Directors

Jay M. Moyes has served on our board of directors since 2011. He has served on the board of directors of Puma Biotechnologies (NYSE: PBYI) since April 2012, and on the board of directors of Achieve Life Sciences from 2018 to the present and on the board of directors and Chairman of the Audit Committee of Osiris Therapeutics (NASDAQ: OSIR), a biosurgical company, from May 2006 until December 2017. He also served as a member of the board of directors and Chairman of the Audit Committee of Integrated Diagnostics, a privately held molecular diagnostics company, from 2011 to 2016. From 2012 to 2014, Mr. Moyes served as a member of the board of directors of Amedica Corporation, a publicly traded orthopedics company, and as Chief Financial Officer from 2013 to 2014. Mr. Moyes was the Chief Financial Officer of Sera Prognostics, Inc. (NASDAQ: SERA), a women's health diagnostics company, from March 2020 to June 2023. From 2008 to 2009, Mr. Moyes served as Chief Financial Officer of CareDx, a publicly traded molecular diagnostics company. Prior to that, he served as Chief Financial Officer of Myriad Genetics, Inc., a publicly held healthcare diagnostics company, from June 1996 until his retirement in November 2007, and as Vice President of Finance from July 1993 until July 2005. From 1991 to 1993, Mr. Moyes served as Vice President of Finance and Chief Financial Officer of Genmark, a privately held genetics company. Mr. Moyes held various positions with the accounting firm of KPMG from 1979 to 1991. He also served as a member of the Board of Trustees of the Utah Life Science Association from 1999 to 2006. Mr. Moyes holds a Master of Business Administration from the University of Utah, a Bachelor of Arts in economics from Weber State University and is formerly a Certified Public Accountant.

Job Titles:

• Member of the Board of Directors
• Chief Executive Officer and President of Sea Star, Inc

Jim Allen was appointed to our board of directors effective October 1, 2019. Mr. Allen is Chief Executive Officer and President of Sea Star, Inc., a real estate development company, and has served in that capacity since he founded the company in February 1989. Mr. Allen has founded multiple companies from concept to full operation involving the development of various technologies, patents, manufacturing processes, and sales, distribution and maintenance programs. Six of his ventures have resulted in sales to publicly-traded companies. One of his companies was sold to Roper Technologies, Inc. and he is currently serving in a consulting capacity for TransCore Atlantic LLC, a Roper Technologies, Inc. Company. He is a named inventor on 29 issued and pending patents. Mr. Allen studied business at Troy University and Auburn University at Montgomery.

Job Titles:

• Chief Financial Officer
• Member of the Management Team
• CFO View Profile

Mr. David McClung has served as our Chief Financial Officer since September 2017 and has been with the Company since September 2013, also serving as Vice President of Finance from March 2016 to August 2017 and as Senior Director of Finance & Controller from September 2013 to February 2016. Mr. McClung has finance and accounting experience in publicly and privately financed organizations, including startup enterprises, large public companies and middle-market businesses. Before joining our company, Mr. McClung served as Director of Finance and Controller at Sonitus Medical, Inc., a privately-held manufacturer of an FDA cleared prosthetic hearing device for the treatment of single-sided deafness and conductive hearing loss. Prior to that, Mr. McClung served as Controller at NextWave Pharmaceuticals, Inc. a specialty pharmaceutical company acquired by Pfizer, Inc. Mr. McClung spent his early career in public accounting and finance functions at other companies, including Matson Navigation, Inc., The Clorox Company and KPMG LLP. Mr. McClung earned a Bachelor of Arts degree in Accounting from Georgia State University, graduating with honors. He is an actively licensed CPA and member of the AICPA and the California Society of CPAs.

Job Titles:

• CEO
• Member of the Board of Directors
• Member of the Management Team
• President
• President & CEO View Profile

Peter Altman, Ph.D. has served as our President and Chief Executive Officer since 2002 and has global responsibility for the development, manufacture and marketing of our therapeutic candidates and products. He was founding Chief Executive Officer from 1999 to 2003 and board member of CareDx (NASDAQ: CDNA) from 1999 to 2014, a developer of a gene-based diagnostics to be used in chronic inflammatory diseases, including cardiac transplantation, coronary artery disease and systemic lupus erythematosus. He was also founding Chief Executive Officer for Lumen Therapeutics from 2004 to 2005, an early-stage pharmaceutical company. He has extensive experience in life science research and product development, is named inventor in 45 U.S. patents, and has authored 40 scientific publications. Dr. Altman currently serves as a director on the board of Oncocyclist Biotech. He received his Ph.D. in Bioengineering/Pharmaceutical Chemistry from the University of California, San Francisco and University of California, Berkeley, his Management of Technology certificate from the Walter A. Haas School of Business at the University of California, Berkeley, and both his Master of Science and Bachelor of Science in Mechanical Engineering from the Columbia University School of Engineering and Applied Sciences. Dr. Altman has been elected Fellow of the American Heart Association.

Job Titles:

• Member of the Board of Directors
• Director of OPKO Health, Inc

Richard Krasno, Ph.D. was appointed to our board of directors in October 2016. Dr. Krasno has served as a director of OPKO Health, Inc. since 2017. Dr. Krasno previously served as a director on the board of Ladenburg Thalmann from 2006 until 2020 and Castle Brands, Inc. from 2014 until 2019. Dr. Krasno served as the executive director of the William R. Kenan, Jr. Charitable Trust from 1999 to 2014 and, from 1999 to 2010, as president of the four affiliated funds. Prior to that, Dr. Krasno was the president of the Monterey Institute of International Studies in Monterey, California. From 2004 to 2012, Dr. Krasno also served as a director of the University of North Carolina Health Care System and served as chairman of the board of directors from 2009 to 2012. From 1981 to 1998, he served as president and chief executive officer of the Institute of International Education in New York. He also served as Deputy Assistant Secretary of Education in Washington, D.C. from 1979 to 1980. Mr. Krasno holds a Bachelor of Science from the University of Illinois and a Ph.D. from Stanford.

Job Titles:

• Member of the Board of Directors